Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001564590-21-019953
Filing Date
2021-04-22
Accepted
2021-04-22 08:30:12
Documents
4
Period of Report
2021-06-08

Document Format Files

Seq Description Document Type Size
1 DEF 14A agle-def14a_20210608.htm DEF 14A 947357
2 GRAPHIC g1l5si5gyvjn000003.jpg GRAPHIC 156295
3 GRAPHIC g1l5si5gyvjn000001.jpg GRAPHIC 6876
4 GRAPHIC g1l5si5gyvjn000002.jpg GRAPHIC 79082
  Complete submission text file 0001564590-21-019953.txt   1282359
Mailing Address 805 LAS CIMAS PARKWAY SUITE 100 AUSTIN TX 78746
Business Address 805 LAS CIMAS PARKWAY SUITE 100 AUSTIN TX 78746 (512) 942-2935
Aeglea BioTherapeutics, Inc. (Filer) CIK: 0001636282 (see all company filings)

EIN.: 464312787 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-37722 | Film No.: 21843334
SIC: 2834 Pharmaceutical Preparations